secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001999371-25-007734
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix appoints former EVP James Hunter to Board; 7,740 option grant at $34.54
-----------------------------------------------------------------------------

- Appointment effective June 12, 2025; Hunter served as EVP Commercial from June 2023 to Dec 2024.
- Received 7,740 stock options at $34.54, vesting at 2026 annual shareholder meeting.
- Hunter led launch of Tonix Medicines and migraine asset acquisitions Zembrace and Tosymra.
- Board addition strengthens commercial expertise ahead of potential TNX-102 SL fibromyalgia launch; PDUFA Aug 15, 2025.
- Not independent under NASDAQ standards due to prior consulting and employment compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125007734/0001999371-25-007734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125007734/tnxp-8k_061325.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-007734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer